 |
274 Diseases |  |
1061 Trials |
|
1061 Trials |  |
12145 News |  |
| 12345678910111213...178179» |
- || Opdivo (nivolumab) / BMS
P2 data, Journal: First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer. (Pubmed Central) - Sep 6, 2024
To our knowledge, the first results from NURE-Combo trial suggest that this combination could expand the therapeutic opportunities of immune-chemotherapy in patients with MIBC.
- | docetaxel / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Journal, Real-world evidence, Real-world: Pathological response and safety of albumin-bound paclitaxel as a neoadjuvant treatment for HER2-positive breast cancer compared to docetaxel combined with anti-HER2 therapy: a real-world study. (Pubmed Central) - Sep 5, 2024
The multivariate analysis revealed that chemotherapy drugs, clinical stage, ER status, and Ki-67 level was the significant factor influencing treatment outcome. These findings offer a valuable reference for the neoadjuvant treatment of patients with HER2-positive breast cancer.
- | cyclophosphamide / Generic mfg., epirubicin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Journal: Neoadjuvant chemotherapy for primary invasive ductal carcinoma of the nipple: A case report. (Pubmed Central) - Sep 5, 2024
Changes in the nipple should be treated cautiously and a pathological biopsy should be performed in a timely manner. Breast cancer occurring in the nipple can be treated with reference to the same type of common breast cancer, and neoadjuvant chemotherapy can also be performed first if neoadjuvant chemotherapy is indicated.
- | albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: On cost-effectiveness analysis, quality-adjusted life years, and cost-effectiveness threshold values of gemcitabine plus nab-paclitaxel versus gemcitabine alone in metastatic pancreatic cancer in the French setting. (Pubmed Central) - Sep 4, 2024
Breast cancer occurring in the nipple can be treated with reference to the same type of common breast cancer, and neoadjuvant chemotherapy can also be performed first if neoadjuvant chemotherapy is indicated. No abstract available
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Journal: Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma. (Pubmed Central) - Sep 3, 2024
No abstract available The alternating sequential administration of the NS and GemOx regimens may be a novel approach for first-line chemotherapy in patients with advanced PDAC requiring further study (ClinicalTrials.gov Identifier: ChiCTR1900024867).
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Case report: outcome of anlotinib treatment in breast cancer patient with brain metastases. (Pubmed Central) - Sep 3, 2024
After the standard first-line treatment including albumin-bound paclitaxel, trastuzumab and pertuzumab, and a second-line treatment involving pyrotinib, capecitabine, and radiotherapy did not produce the desired results, the patient was then administered anlotinib in combination with pyrotinib and letrozole as a third-line treatment, which led to a partial response (PR). The findings suggest that anti-angiogenic therapy, specifically anlotinib, could be regarded as a promising therapeutic option for BC patients with BM.
- | Xermelo (telotristat etiprate) / Ipsen, Lexicon Pharma, TerSera Therap
Preclinical, Journal, PD(L)-1 Biomarker: Telotristat ethyl, a tryptophan hydroxylase inhibitor, enhances antitumor efficacy of standard chemotherapy in preclinical cholangiocarcinoma models. (Pubmed Central) - Sep 3, 2024
Standard chemotherapy regimens for CCA, gemcitabine plus cisplatin (GemCis) or its recently approved combination with durvalumab demonstrate dismal clinical activity, yielding a median survival of 12-14?months...Nab-paclitaxel (NPT) significantly enhanced animal survival (60%), surpassing the marginal effects of TE (11%) or GemCis (9%) in peritoneal dissemination xenografts...Furthermore, TE treatment consistently decreased serotonin levels in all tumours under all therapeutic conditions. This investigation decisively demonstrated the antitumor efficacy of TE across a spectrum of CCA preclinical models, suggesting that combination therapies involving TE, particularly for patients exhibiting serotonin overexpression, hold the promise of improving clinical CCA therapy.
- | Biomarker, Journal, BRCA Biomarker, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: Biomarker-driven targeted therapy in patients with recurrent platinum-resistant epithelial ovarian cancer (BRIGHT): protocol for an open-label, multicenter, umbrella study. (Pubmed Central) - Sep 2, 2024
P2
Recruitment is estimated to be completed by 2024 and results may be published by 2027. ClinicalTrials.gov: NCT05044871.
- | albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Journal: Outcomes After Multimodality Treatment of Pancreatic Cancer in an Unselected Single-Center Cohort. (Pubmed Central) - Sep 2, 2024
Among the 287 patients treated with systemic therapy only, combination chemotherapy was independently associated with longer mOS (11.6 months) as compared to gemcitabine-monotherapy (6.8 months)...In locally advanced PDAC, dRT was associated with longer survival as compared to systemic therapy only. Concerning first-line systemic therapy, our results support the use of combination chemotherapy over single-agent therapy.
- | albumin-bound paclitaxel / Generic mfg.
Journal: Functionalizing Sgc8-Paclitaxel Conjugates with F-Base Modifications: Targeted Drug Delivery with Optimized Cardiac Safety. (Pubmed Central) - Sep 2, 2024
Autophagy pathway analysis showed no discernible differences in Sgc8-F23-PTX-treated cardiomyocytes compared with controls, in contrast to the increased autophagy with nanoparticle albumin-bound-paclitaxel (Nab-PTX)...These findings suggest the safety and efficacy of F-base-modified Sgc8 aptamers for targeted drug delivery, holding potential clinical applications. Further research is warranted for clinical translation and exploration of other drug carriers.
- | albumin-bound paclitaxel / Generic mfg.
Retrospective data, Journal: Safety of nab-paclitaxel following an allergic reaction to paclitaxel: A single institution retrospective study. (Pubmed Central) - Sep 1, 2024
None of the 43 patients had an allergic reaction to subsequent nab-paclitaxel. Our data suggests that the administration of nab-paclitaxel to endometrial cancer or ovarian cancer patients with allergic reactions to paclitaxel is safe and should be considered a preferable treatment option in this clinical situation.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, Metastases: IgA vasculitis induced by carboplatin + nab-paclitaxel + pembrolizumab in a patient with advanced lung squamous cell carcinoma: a case report. (Pubmed Central) - Sep 1, 2024
After discontinuation of pembrolizumab and glucocorticoids, the symptoms immediately resolved. Regular monitoring of skin, blood tests, and urinalysis are necessary, and the possibility of irAE IgA vasculitis should be considered in cases of purpura and AKI during treatment with immune checkpoint inhibitors.
- || Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, AiRuiKa (camrelizumab) / HLB Bio Group
Biomarker, P2 data, Retrospective data, Journal, Tumor microenvironment, PD(L)-1 Biomarker, IO biomarker, Metastases: Tumor microenvironment biomarkers predicting pathological response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma: post-hoc analysis of a single center, phase 2 study. (Pubmed Central) - Sep 1, 2024
P1/2
Regular monitoring of skin, blood tests, and urinalysis are necessary, and the possibility of irAE IgA vasculitis should be considered in cases of purpura and AKI during treatment with immune checkpoint inhibitors. The NCIRPs model that was developed and validated using treatment-na
- | albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Journal, BRCA Biomarker, Circulating tumor DNA, Metastases: Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer. (Pubmed Central) - Aug 31, 2024
Comprehensive ctDNA profiling provides clinically relevant information regarding HRD status. It can be a practical, convenient option for HRD screening in APC.
- || Hansizhuang (serplulimab) / Fosun Pharma
P2 data, Journal, PD(L)-1 Biomarker, IO biomarker: Single-drug Chemotherapy Plus Immunotherapy as First-line Treatment for Stage ? Non-small Cell Lung Cancer Elderly Patients: A Phase II Clinical Trial UNICORN Study. (Pubmed Central) - Aug 31, 2024
It can be a practical, convenient option for HRD screening in APC. This is the first study to evaluate the efficacy and safety of serplulimab combined with either paclitaxel or pemetrexed in elderly treatment-na
- | 5-fluorouracil / Generic mfg.
Biomarker, Journal, Combination therapy, Metastases: First-line Chemotherapy in Combination With Oral Recombinant Methioninase and a Low-methionine Diet for a Stage IV Inoperable Pancreatic-Cancer Patient Resulted in 40% Tumor Reduction and an 86% CA19-9 Biomarker Decrease. (Pubmed Central) - Aug 31, 2024
This is the first study to evaluate the efficacy and safety of serplulimab combined with either paclitaxel or pemetrexed in elderly treatment-na Methionine restriction consisting of o-rMETase and a low-methionine diet, in combination with first-line chemotherapy, was highly effective in a patient with inoperable stage IV pancreatic cancer.
- | Enrollment open: OPPRESS: Stereotactic Body Radiotherapy for Oligo-Progression Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 30, 2024
P3, N=104, Recruiting, Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Methionine restriction consisting of o-rMETase and a low-methionine diet, in combination with first-line chemotherapy, was highly effective in a patient with inoperable stage IV pancreatic cancer. Not yet recruiting --> Recruiting
- albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Liver Lesion in a Patient With Intraductal Tubulopapillary Neoplasm Associated With Invasive Carcinoma and Synchronous Esophageal Adenocarcinoma: Molecular Profiling Helps to Determine the Primary Origin (Exhibit Hall, Cristal Ballroom) - Aug 28, 2024 - Abstract #CAP2024CAP_197;
The patient was started on a chemotherapy regimen using gemcitabine Abraxane. To the best of our knowledge, this is the first case of a patient with synchronous esophageal adenocarcinoma and pancreatic carcinoma associated with ITPN that presented with liver metastasis; the molecular findings were particularly helpful to support the primary origin to be pancreatic tumor.
- || capecitabine / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Clinical, P2 data, Journal, Metastases: Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers: An open-label, non-randomized, phase II clinical trial. (Pubmed Central) - Aug 28, 2024
To the best of our knowledge, this is the first case of a patient with synchronous esophageal adenocarcinoma and pancreatic carcinoma associated with ITPN that presented with liver metastasis; the molecular findings were particularly helpful to support the primary origin to be pancreatic tumor. Nab-paclitaxel plus capecitabine may be an effective and safe first-line treatment strategy for patients with advanced or metastatic BTCs.
- | relacorilant (CORT125134) / Corcept Therap
Journal, Metastases: Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study. (Pubmed Central) - Aug 27, 2024
Relacorilant plus nab-paclitaxel showed modest antitumor activity in heavily pretreated patients with mPDAC, with no new safety signals. Studies of this combination in other indications with a high unmet medical need are ongoing.
- | Lynparza (olaparib) / Merck (MSD), AstraZeneca
Journal, BRCA Biomarker, PARP Biomarker: Germline BRCA1-Mutated Synchronous and Metachronous Pancreatic Acinar Cell Carcinoma With Long-Term Survival. (Pubmed Central) - Aug 27, 2024
Considering that PACC is likely to have BRCA1/2 mutations responsible for HBOC, we need to be aware of the possible presence of multifocal and/or metachronous tumors in patients with PACC. Additionally, patients with PACC should undergo genetic examinations, which would be beneficial in determining treatment strategies and health care for blood relatives.
- | albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Journal, Stroma: Research status of the tumor stroma ratio in prognosis and treatment of pancreatic cancer (Pubmed Central) - Aug 26, 2024
Integration of artificial intelligence deep learning models into traditional pathological and imaging assessments facilitates precise evaluation of the TSR. It can also enable stratification and precision treatment of pancreatic cancer patients based on this index.
- | albumin-bound paclitaxel / Generic mfg.
Preclinical, Journal: Hyaluronidase improves the efficacy of nab-paclitaxel after prolonged angiogenesis inhibition in preclinical models for esophagogastric cancer. (Pubmed Central) - Aug 24, 2024
These findings suggest that the mechanical barrier of HA is the major reason responsible for the resistance developed during prolonged anti-angiogenesis in EGC. Incorporating PEGPH20 into the existing treatment regimen is promising to improve outcomes for patients with EGC.
- || Viracept (nelfinavir) / ViiV Healthcare, Roche
P1 data, P2 data, Journal, Metastases: Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: The phase 1/randomised phase 2 SCALOP-2 trial. (Pubmed Central) - Aug 24, 2024
Dose-escalated CRT may improve local tumour control and is well tolerated when used as consolidative treatment in LAPC but does not impact OS. Nelfinavir use does not improve PFS.
- | ORIC-101 / ORIC Pharma
Journal, Combination therapy, Metastases: ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Nab-Paclitaxel in Patients with Advanced Solid Tumors. (Pubmed Central) - Aug 23, 2024
P1
ORIC-101 with nab-paclitaxel showed limited clinical activity in taxane-resistant solid tumors. Despite clear inhibition of GR pathway signaling, the insufficient clinical signal underscores the challenges of targeting a single resistance pathway when multiple mechanisms of resistance may be in play.
- | docetaxel / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Retrospective data, Journal: Incidence and prognosis of taxane-induced macular edema: a retrospective study from the Japan Clinical REtina Study Group (J-CREST). (Pubmed Central) - Aug 23, 2024
A correlation was found between duration of taxane treatment and VA immediately before discontinuation of anticancer drugs (??=?0.00050; 95% confidence interval: 0.00036-0.00097; P?<?0.05). Although taxane-induced macular edema is reversible, slower anticancer drug discontinuation worsened VA, highlighting the need for regular ophthalmologic evaluation during treatments.
- || Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
Review, Journal: Jejunal sarcomatoid carcinoma: A case report and review of literature. (Pubmed Central) - Aug 22, 2024
Although taxane-induced macular edema is reversible, slower anticancer drug discontinuation worsened VA, highlighting the need for regular ophthalmologic evaluation during treatments. This case suggests that chemotherapy, immunotherapy, plus targeted therapy may represent an optimal treatment for intestinal SCA, meriting further investigation.
- || NRT6008 / Chengdu New Radiomedicine Technology
Trial initiation date, Metastases: Safety and Efficacy of NRT6008 in Patients With Unresectable Locally Advanced Pancreatic Cancer (LAPC) (clinicaltrials.gov) - Aug 21, 2024
P1, N=58, Not yet recruiting, Sponsor: Chengdu New Radiomedicine Technology Co. LTD.
This case suggests that chemotherapy, immunotherapy, plus targeted therapy may represent an optimal treatment for intestinal SCA, meriting further investigation. Initiation date: Mar 2024 --> Sep 2024
- ||| Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics
Trial completion, Combination therapy, Metastases: AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer (clinicaltrials.gov) - Aug 21, 2024
P1, N=76, Completed, Sponsor: AstraZeneca
Initiation date: Mar 2024 --> Sep 2024 Active, not recruiting --> Completed
- |||||||||| TQB2102 / Sino Biopharm
New P3 trial, Metastases: A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer (clinicaltrials.gov) - Aug 20, 2024
P3, N=542, Not yet recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- | albumin-bound paclitaxel / Generic mfg.
Journal: Factors affecting peripheral neuropathy induced by nanoparticle albumin-bound paclitaxel in patients with pancreatic cancer. (Pubmed Central) - Aug 17, 2024
The higher the cumulative dose of Nab-P, treatment cycles and age, the more frequently and severely do the patients experience CIPN. In predicting the severity of CIPN using Cmax, minimally invasive VAMS is a feasible alternative to venous blood sampling.
- | albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Journal: Successful pancreatectomy after conversion-intended chemotherapy using gemcitabine and nab-paclitaxel for unresectable adenosquamous carcinoma of the pancreas: a case report. (Pubmed Central) - Aug 16, 2024
In predicting the severity of CIPN using Cmax, minimally invasive VAMS is a feasible alternative to venous blood sampling. Conversion-intended chemotherapy using gemcitabine and nab-paclitaxel regimen may be effective for ASCP.
- | Retrospective data, Journal, Surgery: Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemotherapy: A multicenter retrospective cohort study (PC-CURE-1). (Pubmed Central) - Aug 16, 2024
Conversion-intended chemotherapy using gemcitabine and nab-paclitaxel regimen may be effective for ASCP. CS, following a favorable response to FOLFIRINOX or GnP chemotherapy, improved initially unresectable PC prognosis (specifically, OS), regardless of the chemotherapy duration.
- || Zepzelca (lurbinectedin) / PharmaMar, Jazz
P2 data, Journal: Phase II study of nab-paclitaxel with gemcitabine for relapsed/refractory small cell lung cancer. (Pubmed Central) - Aug 15, 2024
P2
Further studies are needed to compare this combination with other treatments used for relapsed SCLC, including lurbinectedin, temozolomide, and topotecan. https://clinicaltrials.gov/study/NCT02769832?cond=NCT02769832&rank=1, identifier NCT02769832.
- || AiRuiKa (camrelizumab) / HLB Bio Group
P2 data, Journal: Preoperative administration of camrelizumab combined with chemotherapy for borderline resectable esophageal squamous cell carcinoma (BRES-1): study protocol of a single-arm, open-label, phase II study. (Pubmed Central) - Aug 15, 2024
Registered 11 February 2022. https://www.chictr.org.cn/index.aspx.
- | 5-fluorouracil / Generic mfg.
Journal, Metastases: Metastatic Pancreatic Adenocarcinoma Downstaged to T0N0 with Chemotherapy and Targeted Therapy, Confirmed by Surgical Pathology: A Case Report. (Pubmed Central) - Aug 15, 2024
Due to the history of a hepatic lesion, she received 11 cycles of gemcitabine/Abraxane and a combination of a MEK inhibitor, Mekinist, and a BRAF inhibitor, BRAFTOVI...The patient has recently been seen 9 months after surgery with no evidence cancer recurrence. Additionally, ctDNA remains negative.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Retrospective data, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: The Efficiency and Safety of Triple-Drug Combination of Albumin-Bound Paclitaxel, Anlotinib and PD-1/L1 Inhibitors in the 2nd or Above Line of Advanced NSCLC: A Retrospective Cohort Study. (Pubmed Central) - Aug 13, 2024
Our study displayed that triple-drug combination of nab-ptx, anlotinib and PD-1/L1 inhibitors showed promising efficiency and tolerated cytotoxicity in the 2nd or above line treatment of advanced NSCLC, indicating the potential of such regimen as an important option for second-line treatment of advanced NSCLC. However, due to limitations in patient numbers, its actual clinical value awaits further research confirmation.
- | Journal: Somatic Mutation Profile as a Predictor of Treatment Response and Survival in Unresectable Pancreatic Ductal Adenocarcinoma Treated with FOLFIRINOX and Gemcitabine Nab-Paclitaxel. (Pubmed Central) - Aug 10, 2024
(4) Molecular profiling could play a role in PDAC for predicting outcomes and responses to therapies like FOLFIRINOX and gemcitabine nab-paclitaxel. Integrating genomic data into clinical decision-making can benefit PDAC treatment, though further validation is needed to fully utilize precision oncology in PDAC management.
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
Journal: Spatial proteomic profiling elucidates immune determinants of neoadjuvant chemo-immunotherapy in esophageal squamous cell carcinoma. (Pubmed Central) - Aug 10, 2024
These insights underscore the vital role of integrating spatial proteomics into clinical trials to dissect TME dynamics thoroughly, paving the way for personalized and precise cancer treatment strategies in ESCC. This holistic approach not only enhances our understanding of the mechanistic basis behind drug resistance but also sets a robust foundation for optimizing therapeutic interventions in ESCC.
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Metastases: Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC (clinicaltrials.gov) - Aug 9, 2024
P2, N=100, Recruiting, Sponsor: Beijing Tongren Hospital
This holistic approach not only enhances our understanding of the mechanistic basis behind drug resistance but also sets a robust foundation for optimizing therapeutic interventions in ESCC. Not yet recruiting --> Recruiting
- | New P3 trial, MRI, Metastases: Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI (clinicaltrials.gov) - Aug 9, 2024
P3, N=304, Recruiting, Sponsor: Sun Yat-sen University
- | Enrollment change, Trial completion date, Trial termination: QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. (clinicaltrials.gov) - Aug 9, 2024
P1/2, N=9, Terminated, Sponsor: ImmunityBio, Inc.
Not yet recruiting --> Recruiting N=79 --> 9 | Trial completion date: Oct 2023 --> Jan 2024 | Active, not recruiting --> Terminated; Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention
- | gemcitabine / Generic mfg.
Biomarker, Observational data, Journal, Metastases: Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT study). (Pubmed Central) - Aug 8, 2024
N=79 --> 9 | Trial completion date: Oct 2023 --> Jan 2024 | Active, not recruiting --> Terminated; Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention Genetic polymorphisms from the pharmacokinetics of gemcitabine did not indicate a significant association with efficacy, but COX-2 polymorphisms involved in tumor cell proliferation might affect OS.
- | Lynparza (olaparib) / Merck (MSD), AstraZeneca
Journal, BRCA Biomarker, PARP Biomarker, Metastases: The Initial Journey of Patients with Metastatic Pancreatic Cancer (PaCTO Project): A Nationwide Survey among Portuguese Specialist Physicians. (Pubmed Central) - Aug 8, 2024
Physicians in Portugal support the increasing role of patient-tailored treatments in mPDAC, whose selection should be grounded on tumoral subtyping and molecular profiling. Further efforts to develop multidisciplinary teams, standardized clinical practice, and optimize the implementation of new target therapies are needed.
- || gemcitabine / Generic mfg.
Clinical, Retrospective data, Review, Journal, Combination therapy, Monotherapy, Metastases: Efficacy of first-line combination therapies versus gemcitabine monotherapy for advanced pancreatic cancer: a systematic review and network meta-analysis. (Pubmed Central) - Aug 8, 2024
The analysis revealed that gemcitabine+nab-paclitaxel (GA), GA with platinum and fluorouracil (GA+Plat+FU), gemcitabine with fluorouracil (G+FU), G+Plt+FU, and FOLFIRINOX were associated with superior OS and PFS compared to gemcitabine monotherapy...These findings support the use of gemcitabine-based or fluorouracil-based triplet or quadruplet regimens for better survival outcomes in patients with advanced pancreatic cancer. Further research is warranted to explore the potential benefits of adding chemotherapy agents, such as fluorouracil, to the GA doublet regimen.
- | Keytruda (pembrolizumab) / Merck (MSD)
Retrospective data, Journal, Tumor proportion score, Metastases: Pembrolizumab Plus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After 5 Years of Follow-Up. (Pubmed Central) - Aug 7, 2024
P3
With approximately 5 years of follow-up, pembrolizumab plus chemotherapy provided clinically meaningful and durable improvements in survival outcomes versus chemotherapy alone in patients with previously untreated metastatic NSCLC with PD-L1 TPS less than 1%. These results continue to support pembrolizumab plus chemotherapy as a standard of care in this patient population.
- || pegylated liposomal doxorubicin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Review, Journal: Chemoradiotherapy and nanomedicine: Drug mechanisms and delivery systems. (Pubmed Central) - Aug 7, 2024
Though many challenges remain, the ongoing progress evidences a promising future for both nanomedicine and chemoradiotherapy. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Therapeutic Approaches and Drug Discovery > Nanomedicine for Cardiovascular Disease Therapeutic Approaches and Drug Discovery > Emerging Technologies.
- || oleclumab (MEDI9447) / AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
Clinical, P1/2 data, Journal, PD(L)-1 Biomarker, Metastases: A Phase 1b/2 Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. (Pubmed Central) - Aug 6, 2024
P1b/2
This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Therapeutic Approaches and Drug Discovery > Nanomedicine for Cardiovascular Disease Therapeutic Approaches and Drug Discovery > Emerging Technologies. Although the safety profile was acceptable, this study did not meet its primary efficacy endpoint.
- | Phase classification: FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov) - Aug 6, 2024
P2, N=716, Recruiting, Sponsor: Fudan University
Although the safety profile was acceptable, this study did not meet its primary efficacy endpoint. Phase classification: P1/2 --> P2
- | gemcitabine / Generic mfg.
Journal: Preoperative chemotherapy with Gemcitabine for pancreatic cancer causes zinc deficiency. (Pubmed Central) - Aug 5, 2024
The preoperative chemotherapy consistently reduced the serum zinc concentrations in the PC patients, regardless of their regimen such as GEM + S1 and GEM + nab-PTX. Monitoring the serum zinc concentration and appropriate zinc supplementation may be essential for PC patients undergoing preoperative chemotherapy and pancreatectomy.